List view / Grid view
Scientists have found that when two specific genes are deleted in benign tumour tissue in the intestines, it more rapidly develops into a tumour that is more likely to become cancerous.
A study has shown that T cells are driven to attack tumours by IL-2 and Blimp-1 in mice, which researchers say could form the basis of cancer therapies.
A study has revealed that activation of syndecan-4 sensory protrusions extending from cells may be a future target for cancer therapy.
A study has shown that using three antibodies with two different mechanisms of action could be a novel way to improve immuno-oncology treatments.
Researchers have created an algorithm that locates and analyses DNA structures which are linked to the development of certain diseases.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
Humanised immune system (HIS) models have enabled numerous in vivo evaluations of immuno-modulating biologic drugs and ongoing improvements continue to extend their utility. Paul Volden explores the application of HIS models in precision and personalised medicine with a focus on biologics, including how HIS models are used, why they are…
Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. Steve and Carol Trim discuss the challenges of the hit-to-lead journey with these non-standard hits.
New research has categorised hundreds of cancers based on their common protein mutations, highlighting cell components and tumour microenvironments as possible new therapy targets.
A new study has presented a potential strategy for a universal human cancer vaccine. This article delves into the researchers’ findings, exploring their methodologies and results.
A study has demonstrated that dendritic cells play a key role in inflammation and how TNF inhibitors can prevent them from fighting infections.
Central to reproducibility in biomedical research is the ability to use well-characterised and defined reagents. The CPTAC Antibody Portal serves as a National Cancer Institute community resource that provides access to many standardised renewable affinity reagents to cancer-associated targets and accompanying characterisation data. Nikki Withers spoke to Dr Tara Hiltke…
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
A new chemical tool has been used to identify hundreds of modified proteins which allows new insights to major diseases.
CAR T-cell therapy has caused quite a stir in the immunotherapy world, but it is a process that requires precision and care. Quantitative polymerase chain reaction (qPCR) has thus far been the stalwart technique for providing a check on copy numbers, but here Ping Jin explains why droplet digital PCR…
